Bedrijfsoverzicht
Nano-X Imaging Ltd. is a specialized developer within the healthcare sector that focuses on creating commercial-grade tomographic imaging devices equipped with digital X-ray sources, alongside the provision of teleradiology services and artificial intelligence applications for real-world medical imaging. Operating specifically within the medical devices industry, the company leverages its technological solutions to enhance diagnostic capabilities in clinical settings through its Nanox Multi Source System. As of the latest reporting period, the entity demonstrates a market capitalization of $157.97M, which positions it as a mid-sized player in the broader medical technology landscape, supported by an annual revenue of $12.30M and a workforce of 165 employees. The combination of a market cap under $200M and revenue slightly above $12M indicates that the company is currently in a growth phase where capital markets are pricing in future technological adoption rather than current profitability, reflecting a strategy that prioritizes R&D and market penetration over immediate earnings generation.
Financiële gezondheid
The company reported a revenue of $12.30M over the trailing twelve months, yet this figure contrasts sharply with a net income of -$55,706,000 and an EBITDA of -$45,925,000, revealing a cost structure where operating expenses significantly outweigh generated income to the extent that the business is running at a substantial loss. This financial profile results in a free cash flow of -$26,877,750, indicating that the company is burning cash at a rate that requires continuous external financing or cash reserve depletion to sustain operations. The margin analysis shows a gross margin of -98.0%, an operating margin of -413.0%, and a profit margin of 0.0%, which collectively suggest that the company's direct costs and overhead expenses are disproportionately high relative to its sales, a typical characteristic of early-stage biotech or medical device firms developing proprietary hardware. Despite the significant debt load of $7.88M, the company holds $45.19M in cash, creating a net cash position that suggests a conservative liquidity stance despite the negative debt-to-equity ratio of 5.03, which technically indicates leverage but is offset by substantial cash reserves. The current ratio stands at 4.14, signaling strong short-term liquidity and the ability to meet obligations as they come due without immediate distress. Furthermore, the return on equity of -34.8% and return on assets of -20.0% demonstrate that management has not yet achieved positive capital efficiency, as the company is currently destroying value per unit of shareholder equity and assets deployed.
Waarderingsbeoordeling
Valuation metrics for Nano-X Imaging present a complex picture, with a trailing P/E ratio of N/A due to losses and a forward P/E of -7.44, implying that the market expects earnings to remain negative or requires significant improvement before traditional profitability multiples become relevant. The price-to-book ratio is calculated at 0.95, indicating that the stock is trading at 95% of its book value, which suggests the market is not currently assigning a significant premium to the company's intangible assets or future growth prospects. When looking at alternative valuation multiples, the price-to-sales ratio stands at 12.84 and the EV/EBITDA is -2.42, figures that suggest investors are pricing the company based on its revenue generation potential and market share opportunities rather than current earnings power or cash flow generation. The stock has experienced significant volatility, trading within a 52-week range defined by a high of $5.86 and a low of $2.11. Based on the available data points, the current market capitalization reflects a position well below the 52-week high, suggesting the stock has retraced considerably from its recent peak levels. Additionally, the beta value of 1.38 indicates that the stock price is expected to be 38% more volatile than the broader market, reflecting the high risk profile associated with small-cap medical device developers.
Growth & Income
The company has demonstrated a revenue growth rate of 13.7% year over year, while earnings growth is marked as N/A due to the absence of positive earnings in the prior period, highlighting a scenario where top-line expansion is occurring in the absence of bottom-line profitability. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, meaning that all generated cash is retained within the business to fund operations, R&D, and capital expenditures rather than being distributed to shareholders. This reinvestment strategy is consistent with the company's development stage, where capital is directed toward scaling the Nanox Multi Source System and advancing its artificial intelligence applications rather than providing immediate income to investors. The overall growth and income profile for Nano-X Imaging is characterized by strong revenue expansion coupled with significant cash burn, presenting a high-risk, high-reward dynamic typical of companies attempting to transition from product development to commercial profitability in the competitive medical devices sector.